Bio-Thera(SH:688177)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥74,220,560.73, representing a year-on-year increase of 23.08%[5] - The net profit attributable to shareholders was -¥110,363,404.74, with a net profit excluding non-recurring gains and losses of -¥122,886,437.18[5] - The net loss for Q1 2022 was CNY -110,363,404.74, slightly higher than the net loss of CNY -109,151,939.71 in Q1 2021[31] - The total comprehensive income attributable to the parent company was -110,360,149.72 RMB, slightly worse than -109,152,056.29 RMB in the previous year[33] - Basic and diluted earnings per share were both -0.27 RMB, compared to -0.26 RMB in Q1 2021[33] Cash Flow - The net cash flow from operating activities was -¥56,794,194.40[5] - The net cash flow from operating activities for Q1 2022 was CNY -57,439,540.21, an improvement compared to CNY -122,851,087.03 in Q1 2021, showing a reduction in cash outflow of 53.3%[55] - Cash received from sales of goods and services was 132,161,441.42 RMB, significantly up from 65,966,491.49 RMB in the same quarter last year[37] - Total operating cash inflows amounted to 149,250,669.45 RMB, compared to 82,782,177.81 RMB in Q1 2021[37] - The net cash flow from investment activities was -162,230,429.04 RMB, a decline from 56,104,913.68 RMB in Q1 2021[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,480,168,294.69, down 5.26% from the end of the previous year[8] - Total liabilities decreased from CNY 530,269,870.06 to CNY 503,016,234.70, representing a reduction of approximately 5.2%[25] - The company's total equity decreased from CNY 2,089,178,501.28 to CNY 1,978,822,930.19, a decline of 5.3%[48] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,673[12] - The largest shareholder, Guangzhou Qixi Group Co., Ltd., held 38.64% of the shares[12] - The top ten shareholders include entities such as Anhui Huizhi Fu Venture Capital Co., Ltd., holding 1,855,947 shares, which is approximately 4.4% of the total shares[14] Research and Development - Research and development expenses totaled ¥141,955,831.99, accounting for 191.26% of operating revenue, a decrease of 34.36 percentage points compared to the previous year[8] - Research and development expenses for Q1 2022 amounted to CNY 141,955,831.99, up from CNY 136,058,889.03 in Q1 2021, indicating a rise of approximately 4.4%[28] Market and Future Outlook - The company has not reported any new product launches or technological advancements during the quarter[17] - There are no significant market expansion or merger and acquisition activities disclosed in the current report[17] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[17] Financial Statements - The financial statements for the quarter are unaudited, indicating that the figures may be subject to change upon final audit[19]